NASDAQ · ARCT
Arcturus Therapeutics Holdings Inc.
Healthcare · Biotechnology
$13.03▼ 1.36% ($0.18)at close
As of 4:00 PM ET
Market cap
$370.35M
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
9 of 10 projected years produce negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
Data notes
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
- 10-yr revenue CAGR
- 0.8%
- Ending operating margin
- 0.0%
- Discount rate
- 18.9%
USD · TTM ending Jun 30, 2026 · Price used $13.03 · Price Oct 2, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 40.45% over the last year. Revenue declined 79.07% over the trailing twelve months. Operating margin moved from -63.82% to -433.36%. Free cash flow declined 12.11% over the trailing twelve months.
What the market seems to be pricing
The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/S, investors are still discounting lower future earnings power.
What would invalidate this read
Operating margin stands at -433.36%. Revenue declined 79.07% — this read reverses if that trend stabilizes. Free cash flow fell 12.11% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Return analysis
Company profile
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States.
Market multiples
Stock splits
Every 7 shares became 1
Profitability & growth
Analyst consensus
12
Buy
5
Hold
4
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 9, 2026
Q3 FY26 · EPS est -$0.67 · Revenue est $8M
View
Institutional Sentiment
Arcturus Therapeutics Holdings Inc. · ARCT
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.